Neural Regeneration Research ›› 2024, Vol. 19 ›› Issue (6): 1212-1220.doi: 10.4103/1673-5374.385850

Previous Articles     Next Articles

Long non-coding RNAs with essential roles in neurodegenerative disorders

Wandi Xiong1, *, Lin Lu2, 3, 4, 5, Jiali Li1, 3, 4, *   

  1. 1Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, the Chinese Academy of Sciences, Kunming, Yunnan Province, China; 2Tsinghua-Peking Center for Life Sciences, Beijing, China; 3National Institute on Drug Dependence, Peking University, Beijing, China; 4PKU/McGovern Institute for Brain Research, Peking University, Beijing, China; 5Institute of Mental Health, National Clinical Research Center for Mental Disorders, Key Laboratory of Mental Health and Peking University Sixth Hospital, Peking University, Beijing, China
  • Online:2024-06-15 Published:2023-11-17
  • Contact: Wandi Xiong, MD, xiongwandi@mail.kiz.ac.cn; Jiali Li, PhD, jialili@bjmu.edu.cn.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, Nos. 91649119 and 92049105 (both to JL).

Abstract: Recently, with the advent of high-resolution and high-throughput sequencing technologies, an increasing number of long non-coding RNAs (lncRNAs) have been found to be involved in the regulation of neuronal function in the central nervous system with specific spatiotemporal patterns, across different neurodegenerative diseases. However, the underlying mechanisms of lncRNAs during neurodegeneration remain poorly understood. This review provides an overview of the current knowledge of the biology of lncRNAs and focuses on introducing the latest identified roles, regulatory mechanisms, and research status of lncRNAs in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Finally, this review discusses the potential values of lncRNAs as diagnostic biomarkers and therapeutic targets for neurodegenerative diseases, hoping to provide broader implications for developing effective treatments.

Key words: Alzheimer’s disease, amyotrophic lateral sclerosis, biomarker, Huntington’s disease, long non-coding RNAs, neurodegenerative diseases, Parkinson’s disease, therapy, transcriptional regulation, translational regulation